Form 4: Contineum Therapeutics Director, Troy A. Ignelzi, Reports Stock Option Grant

Director Troy A. Ignelzi reports the acquisition of stock options in Contineum Therapeutics, Inc.

Summary

• On May 20, 2024, Troy A. Ignelzi, a director of Contineum Therapeutics, Inc., reported the acquisition of 23,150 stock options.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Plan.
• The exercise price of the options is $15.71.
• One-third of the option shares vest and become exercisable on May 20, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to continuous service.
• The options expire on May 19, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it is a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing value creation.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-third after one year and the remainder over the subsequent two years is a typical vesting arrangement.
• Comparing the size of the grant to similar companies and director compensation packages would provide further context.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to increased shareholder value.

Key Dates